|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Associations between serum NPY concentration and other metabolic and inflammatory markers, and 215 SNPs in 21 genes (NPY gene, NPY receptor genes and genes encoding arcuate nucleus NPY neuron receptors) were studied in 180 patients with schizophrenia on clozapine treatment.
|
27837667 |
2017 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
DISC1 dysfunction may be involved in the pathogenesis of schizophrenia through the impairment of the NPY neuronal network.
|
28073591 |
2017 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We provide evidence from this independent Australian postmortem cohort that ErbB4-JMa expression is elevated in schizophrenia and is linked to deficits in dendrite-targeting somatostatin, neuropeptide Y and vasoactive intestinal peptide interneurons.
|
24636039 |
2014 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
We provide evidence from this independent Australian postmortem cohort that ErbB4-JMa expression is elevated in schizophrenia and is linked to deficits in dendrite-targeting somatostatin, neuropeptide Y and vasoactive intestinal peptide interneurons.
|
24636039 |
2014 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Because NPY is a potent orexigenic peptide stimulating food intake, and genetic variation of the gene has been shown to influence development of obesity, we investigated the impact of NPY polymorphisms on antipsychotic-induced BWG.We analyzed 5 polymorphisms in the NPY gene (rs10551063, rs16147, rs5573, rs5574, and rs16475) in schizophrenia subjects (n = 226), treated mostly with clozapine and olanzapine for up to 14 weeks.
|
23277265 |
2013 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In addition, neuropeptide Y (NPY), which is a phenotypic marker of a sub-population of GAD1-containing interneurons, has shown reduced expression in the prefrontal cortex in subjects with schizophrenia, suggesting that dysfunction of the NPY+ cortical interneuronal sub-population might be a core feature of this devastating disorder.
|
20125089 |
2010 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
To clarify NPY's role in schizophrenia, we investigated a genetic animal model for Y(1) deficiency in regard to (i) acoustic startle response (ASR), (ii) habituation to ASR and (iii) sensorimotor gating [i.e. prepulse inhibition (PPI)] using two different PPI protocols.
|
20096928 |
2010 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the NPY -485C>T polymorphism may not confer susceptibility to schizophrenia, at least in our sample.
|
19150389 |
2009 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
These findings suggest that the alterations in SST-containing interneurons in schizophrenia and schizoaffective disorder are selective for the subset that do not express NPY mRNA, and that lower NPY mRNA expression in the superficial white matter may distinguish subjects with schizoaffective disorder from those with schizophrenia.
|
19804960 |
2009 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that the alterations in SST-containing interneurons in schizophrenia and schizoaffective disorder are selective for the subset that do not express NPY mRNA, and that lower NPY mRNA expression in the superficial white matter may distinguish subjects with schizoaffective disorder from those with schizophrenia.
|
19804960 |
2009 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Subjects with schizophrenia showed deficits in NPY and PV mRNAs.
|
19121517 |
2009 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that schizophrenia is associated with alterations in inhibitory inputs from SST/NPY-containing and CCK-containing subpopulations of GABA neurons and in the signaling via certain GABA(A) receptors that mediate synaptic (phasic) or extrasynaptic (tonic) inhibition.
|
17471287 |
2008 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Variants in the genes coding for dopamine-D2 receptor, brain-derived neurotrophic factor (BDNF), neuropeptide Y (NPY), neuregulin 1, reelin and synapsin 3 showed association with schizophrenia, although few subjects were found in the minority allele for the two latter variants.
|
17366345 |
2007 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We examined the hypothesis that -485 T, a novel polymorphism in the promoter region of the neuropeptide Y gene which was shown to be associated with schizophrenia in our previous paper, confers susceptibility to the disease.
|
17066479 |
2007 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
No association between the -399 C > T polymorphism of the neuropeptide Y gene and schizophrenia, unipolar depression or panic disorder in a Danish population.
|
16390370 |
2006 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the polymorphisms at the NPY and YWHAH genes are unlikely to be linked with genetic susceptibility to schizophrenia.
|
15814194 |
2005 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
These results suggest that the -485T allele in NPY may confer susceptibility to schizophrenia by decreasing the neuropeptide in brains.
|
12875921 |
2003 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that the -485T allele in NPY may confer susceptibility to schizophrenia by decreasing the neuropeptide in brains.
|
12875921 |
2003 |